ANNA MANDALAKAS to Microbial Sensitivity Tests
This is a "connection" page, showing publications ANNA MANDALAKAS has written about Microbial Sensitivity Tests.
Connection Strength
0.228
-
Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing. Nat Commun. 2026 Jun 11; 17(1).
Score: 0.048
-
Application of FreezeTB, a targeted nanopore sequencing assay, for identification of drug resistance and lineages among pulmonary tuberculosis cases in Alaska. Microbiol Spectr. 2026 Jan 06; 14(1):e0233525.
Score: 0.046
-
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023 04; 23(4):e122-e137.
Score: 0.038
-
Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children. Cochrane Database Syst Rev. 2022 09 06; 9:CD013359.
Score: 0.037
-
Management of drug-resistant tuberculosis. Lancet. 2019 09 14; 394(10202):953-966.
Score: 0.030
-
Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019 06 01; 23(6):645-662.
Score: 0.029